[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100396485":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":12,"responsibleParty":33,"collaborators":10,"id":37,"slug":10,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":10,"eligibilityCriteria":42,"healthyVolunteers":38,"sex":43,"minAge":44,"maxAge":10,"enrollmentInfo":45,"targetDuration":10,"studyType":48,"phases":10,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":15,"whyStopped":10,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"University Hospital, Gentofte, Copenhagen","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"PFBIO-EXA",null,"All patients recruited for PFBIO-EXA from the original PFBIO cohort are included into the cohort.",[13],{"facility":14,"status":15,"city":16,"state":17,"zip":18,"country":19,"countryCode":20,"cosmosGeoPoint":21,"geoPoint":26,"contacts":27},"Herlev and Gentofte Hospital","RECRUITING","Hellerup","Copenhagen","2900","Denmark","DK",{"type":22,"coordinates":23},"Point",[24,25],12.57093,55.73204,{"lat":25,"lon":24},[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Nils Hoyer, MD PhD","CONTACT","+45 38674200","nils.hoyer@regionh.dk",{"type":34,"investigatorFullName":35,"investigatorTitle":36,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Nils Hoyer","Principal Investigator","100396485",false,"NCT04442711","Cohort of IPF Patients Experiencing an Exacerbation","Pulmonary Fibrosis Biomarkers During Exacerbation","Inclusion Criteria:\n\n* Admitted with an increase in respiratory symptoms\n* Already included in PFBIO or included simultaneously in PFBIO and PFBIO-EXA\n* Age at least 18 years\n\nExclusion Criteria:\n\n* Unable to provide informed consent","ALL","18 Years",{"count":46,"type":47},50,"ESTIMATED","OBSERVATIONAL","Extension of the PFBIO cohort which includes patients with newly diagnosed idiopathic pulmonary fibrosis (IPF) for longitudinal follow-up for up to 5 years.\n\nIn the PFBIO-EXA extension, patients are included if they experience an exacerbation, or other increase in respiratory symptoms requiring hospital admission, for further collection of clinical and biological data.",[51],"Idiopathic Pulmonary Fibrosis",[53,54,55,56,57,58],"Exacerbation","Hospitalization","Biomarkers","Outcome","Prognosis","Diagnosis","2023-12-21",{"date":61,"type":62},"2023-12-22","ACTUAL",{"date":64,"type":62},"2020-06-13",{"date":66,"type":47},"2028-12-31",{"name":5,"class":6},1]